Enteric Hyperoxaluria Clinical Trial
Official title:
Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)
The purpose of this study is to determine the efficacy, durability and long-term safety of reloxaliase in patients with enteric hyperoxaluria.
This is a phase 3, global, multi-center, randomized, double-blind, placebo-controlled study. This study is designed to determine the short- and long-term efficacy of reloxaliase in terms of reducing urinary oxalate excretion and clinical benefits compared to placebo. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04629170 -
Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria
|
Phase 1 | |
| Recruiting |
NCT05650112 -
Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria
|
Phase 1 | |
| Recruiting |
NCT05124886 -
Gut Kidney Axis in Enteric Hyperoxaluria
|
N/A | |
| Completed |
NCT03456830 -
Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria
|
Phase 3 | |
| Completed |
NCT05377112 -
Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome
|
Early Phase 1 | |
| Terminated |
NCT04909723 -
Safety, Tolerability, and Pharmacodynamics of NOV-001 in Adult Subjects
|
Phase 1/Phase 2 | |
| Completed |
NCT03391804 -
Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
|
Phase 2 | |
| Completed |
NCT00588120 -
Enteric Oxalate Absorption Study in Unclassified Hyperoxaluria
|
Phase 1 |